Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ZUMA-1: safety and efficacy of axicabtagene in refractory non-Hodgkin lymphoma patients

Sattva Neelapu • 29 May 2020
ASCO 2020
Follicular Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel
ZUMA-1

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the ZUMA-1 study (NCT02348216), investigating the safety and efficacy of axicabtagene ciloleucel, CAR-T cell therapy, in relapsed, aggressive follicular lymphoma and marginal zone lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sattva Neelapu

0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022
2:43
Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals